In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli-Reference-Cited by-同舟云学术

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli

Published:2018-08 Issue:8 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Schmidt-Malan Suzannah M.¹,Mishra Avisya J.¹,Mushtaq Ammara¹,Brinkman Cassandra L.¹,Patel Robin¹²

Affiliation:

1. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

2. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Abstract

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam–β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli.

Funder

Merck

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00533-18

Reference33 articles.

1. Emerging Issues in Gram-Negative Bacterial Resistance

2. Imipenem Resistance of Enterobacter aerogenes Mediated by Outer Membrane Permeability

3. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance